Evidence map›Paper›PMID 37765308›Full record

ArticlePharmaceutics2023

A New Paclitaxel Formulation Based on Secretome Isolated from Mesenchymal Stem Cells Shows a Significant Cytotoxic Effect on Osteosarcoma Cell Lines.

Alessia Giovanna Santa Banche Niclot, Elena Marini, Ivana Ferrero, Francesco Barbero, Elena Rosso, Ivana Fenoglio, Alessandro Barge, Augusto Pessina, Valentina Coccè, Francesca Paino and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alessia Giovanna Santa Banche NiclotDepartment of Public Health and Paediatrics, The University of Turin, Piazza Polonia 94, 10126 Torino, Italy.
Elena MariniDepartment of Public Health and Paediatrics, The University of Turin, Piazza Polonia 94, 10126 Torino, Italy.ORCID 0000-0001-9793-3701
Ivana FerreroStem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health and Science of Turin, 10126 Torino, Italy.
Francesco BarberoDepartment of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Turin, Italy.ORCID 0000-0001-8704-0651
Elena RossoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
Ivana FenoglioDepartment of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Turin, Italy.ORCID 0000-0002-6946-3105
Alessandro BargeDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0003-4638-6634
Augusto PessinaCRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-0521-8266
Valentina CoccèCRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-9451-9529
Francesca PainoCRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-3186-1888
Katia MareschiDepartment of Public Health and Paediatrics, The University of Turin, Piazza Polonia 94, 10126 Torino, Italy.ORCID 0000-0003-2889-0394
Franca FagioliDepartment of Public Health and Paediatrics, The University of Turin, Piazza Polonia 94, 10126 Torino, Italy.ORCID 0000-0002-9257-900X
University of Turin · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) represents a rare cancer with an unfavorable prognosis that needs innovative treatment. The aim was to isolate a secretome from mesenchymal stem cells (MSCs) that are treated with paclitaxel (PTX)-containing microvesicles as a drug delivery system and analyze its cytotoxic effects on OS cell lines (SJSA, MG63, and HOS).

methodsThree batches of secretome (SECR-1, SECR-2, and SECR-3) were produced from three bone marrow (BM) MSCs samples treated for 24 h with 15 µg/mL of PTX or with a standard medium. The viability of the OS cell lines after 5 days of exposure to SECR-1-2-3 (pure and diluted to 1:2 and 1:4) was analyzed with an MTT assay. The same SECR batches were analyzed with high-performance liquid chromatography (HPLC) and with a nanoparticle tracking assay (NTA).

resultsA statistically significant decrease in the viability of all OS cell lines was observed after treatment with SECR-PTX 1-2-3 in a dose-response manner. The NTA analyses showed the presence of nanoparticles (NPs) with a mean size comparable to that of extracellular vesicles (EVs). The HPLC analyses detected the presence of PTX in minimal doses in all SECR batches.

conclusionsThis proof-of-concept study showed that the conditioned medium isolated from MSCs loaded with PTX had a strong cytotoxic effect on OS cell lines, due to the presence of EV and PTX.

Indexed as

drug delivery systemmesenchymal stem cellsosteosarcomapaclitaxelsecretome

Identifiers

PMID37765308
PMCPMC10537652
OpenAlexW4386874127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.